Physician profile
Julie E Polson
NPI 1154350270
$8,298.00
in general payments reported to CMS, 2019-2025
35 companies · $729 in 2025
The $729 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $1,350 · 2021: $1,676 · 2022: $1,655 · 2023: $976 · 2024: $755 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,186.53 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $902.15 | 2019-2025 | Trulance, Xifaxan |
| Genzyme Corporation | $724.15 | 2022-2025 | |
| Celgene Corporation | $523.72 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $384.89 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $315.40 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $309.74 | 2023-2025 | Dupixent |
| Pfizer INC. | $266.51 | 2019-2022 | |
| Braintree Laboratories, INC. | $240.31 | 2019-2024 | Suflave, Sutab |
| Qol Medical, LLC | $192.43 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $142.67 | 2019-2023 | Linzess |
| Medtronic, INC. | $127.14 | 2022 | |
| Janssen Biotech, INC. | $122.71 | 2020-2025 | Tremfya |
| Fresenius Kabi USA, LLC | $92.24 | 2023 | Idacio |
| Merck Sharp & Dohme LLC | $68.99 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $68.28 | 2024-2025 | Vegzelma |
| Organon LLC | $67.53 | 2021-2023 | Renflexis |
| Lilly USA, LLC | $65.28 | 2023-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $55.30 | 2021-2022 | |
| Ardelyx, INC. | $54.04 | 2025 | Ibsrela |
| Amgen INC. | $47.10 | 2020 | |
| Ucb, INC. | $45.66 | 2019 | |
| Apollo Endosurgery US INC | $35.25 | 2021 | |
| Ethicon US, LLC | $33.27 | 2019 | |
| Alexion Pharmaceuticals, INC. | $33.06 | 2019 | |
| Ferring Pharmaceuticals INC. | $30.17 | 2020-2021 | |
| Alfasigma USA, INC. | $30.04 | 2021 | |
| Echosens North America, INC. | $24.53 | 2024 | Fibroscan |
| Tetraphase Pharmaceuticals, INC. | $23.21 | 2019 | |
| Novo Nordisk INC | $23.16 | 2024 | Wegovy |
| Intercept Pharmaceuticals, INC. | $15.81 | 2020 | |
| Daiichi Sankyo INC. | $12.40 | 2020 | |
| Shionogi INC | $12.18 | 2019 | |
| Allergan, INC. | $11.11 | 2019 | |
| Endo Pharmaceuticals INC. | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Polson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.